Prognostic significance of EpCAM-positive disseminated tumor cells in rectal cancer patients with stage i disease

American Journal of Surgical Pathology

Volumn 36, Issue 12, 2012, Pages 1809-1816

  Dhayat, Sameer ^a   Sorescu, Sorina ^a   Vallböhmer, Daniel ^a   Kraus, Sebastian ^a   Baldus, Stephan Ernst ^a   Rehders, Alexander ^a   Kröpil, Feride ^a   Krieg, Andreas ^a   Knoefel, Wolfram Trudo ^a   Stoecklein, Nikolas Hendrik ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

disseminated tumor cells; epithelial cell adhesion molecule; lymphatic dissemination; peritumoral lymphangiogenesis; stage I rectal cancer

Indexed keywords

CELL ADHESION MOLECULE; DIAGNOSTIC AGENT; EPCAM PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; CANCER STAGING; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RECTUM TUMOR; RETROSPECTIVE STUDY; TIME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; BIOPSY; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ENDOTHELIUM, LYMPHATIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870067112     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318265288c     Document Type: Article

References (85)

1. Bulow S, Christensen IJ, Harling H, et al. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg. 2003;90:974-980.
2. Chok KS, Law WL. Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer. World J Surg. 2007;31:1485-1490.
3. Wichmann MW, Muller C, Hornung HM, et al. Results of longterm follow-up after curative resection of Dukes A colorectal cancer. World J Surg. 2002;26:732-736.
4. Middleton PF, Sutherland LM, Maddern GJ. Transanal endoscopic microsurgery: a systematic review. Dis Colon Rectum. 2005;48:270-284.
5. Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236:522-529; discussion 529-530.
6. Stamos MJ, Murrell Z. Management of early rectal T1 and T2 cancers. Clin Cancer Res. 2007;13:6885s-6889s.
7. Chang AJ, Nahas CS, Araujo SE, et al. Early rectal cancer: local excision or radical surgery? J Surg Educ. 2008;65:67-72.
8. De Graaf EJ, Doornebosch PG, Tollenaar RA, et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur J Surg Oncol. 2009;35:1280-1285.
9. Tsai BM, Finne CO, Nordenstam JF, et al. Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum. 2010;53:16-23.
10. Bach SP, Hill J, Monson JR, et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009;96:280-290.
11. Doornebosch PG, Zeestraten E, de Graaf EJ, et al. Transanal endoscopic microsurgery for T1 rectal cancer: size matters! Surg Endosc. 2012;26:551-557.
12. Morino M, Allaix ME, Caldart M, et al. Risk factors for recurrence after transanal endoscopic microsurgery for rectal malignant neoplasm. Surg Endosc. 2011;25:3683-3690.
13. Hermsen PE, Nonner J, De Graaf EJ, et al. Recurrences after transanal excision or transanal endoscopic microsurgery of T1 rectal cancer. Minerva Chir. 2010;65:213-223.
14. Salinas HM, Dursun A, Klos CL, et al. Determining the need for radical surgery in patients with T1 rectal cancer. Arch Surg. 2011;146:540-543.
15. Wu Y, Wu YY, Li S, et al. TEM and conventional rectal surgery for T1 rectal cancer: a meta-analysis. Hepatogastroenterology. 2011; 58:364-368.
16. Doornebosch PG, Ferenschild FT, de Wilt JH, et al. Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Dis Colon Rectum. 2010;53:1234-1239.
17. Paulson EC, Mitra N, Sonnad S, et al. National Cancer Institute designation predicts improved outcomes in colorectal cancer surgery. Ann Surg. 2008;248:675-686.
18. Kubuschok B, Passlick B, Izbicki JR, et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol. 1999;17:19-24.
19. Passlick B, Izbicki JR, Kubuschok B, et al. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg. 1996;61:177-182; discussion 183.
20. Passlick B, Kubuschok B, Izbicki JR, et al. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg. 1999;68:2053-2058.
21. Passlick B, Pantel K, Kubuschok B, et al. [Simultaneous immuno-cytochemical detection of tumor cells in lymph nodes and in bone marrow of patients with resectable bronchial carcinomas]. Langen-becks Arch Chir Suppl Kongressbd. 1998;115:21-24.
22. Davidson BR, Sams VR, Styles J, et al. Detection of occult nodal metastases in patients with colorectal carcinoma. Cancer. 1990;65:967-970.
23. Greenson JK, Isenhart CE, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer. 1994;73:563-569.
24. Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:60-70.
25. Tschmelitsch J, Klimstra DS, Cohen AM. Lymph node micro-metastases do not predict relapse in stage II colon cancer. Ann Surg Oncol. 2000;7:601-608.
26. Hosch S, Kraus J, Scheunemann P, et al. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res. 2000;60:6836-6840.
27. Hosch SB, Knoefel WT, Metz S, et al. Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas. 1997;15:154-159.
28. Hosch SB, Stoecklein NH, Izbicki Jr. Molecular markers and staging of early esophageal cancer. Langenbecks Arch Surg. 2003; 388:77-82.
29. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188-1194.
30. Scheunemann P, Stoecklein NH, Hermann K, et al. Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance. Langenbecks Arch Surg. 2009;394:105-113.
31. Scheunemann P, Stoecklein NH, Rehders A, et al. Frequency and prognostic significance of occult tumor cells in lymph nodes in patients with adenocarcinoma of the papilla of Vater. HPB (Oxford). 2007;9:135-139.
32. Scheunemann P, Stoecklein NH, Rehders A, et al. Occult tumor cells in lymph nodes as a predictor for tumor relapse in pancreatic adenocarcinoma. Langenbecks Arch Surg. 2008;393:359-365.
33. Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 2008;13:441-453.
34. Stoecklein NH, Siegmund A, Scheunemann P, et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer. 2006;6:165-172.
35. Raffel A, Eisenberger CF, Cupisti K, et al. Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol. 2010;162:391-398.
36. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002;82:1255-1257.
37. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
38. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19:417-428.
39. Adell G, Boeryd B, Franlund B, et al. Occurrence and prognostic importance of micrometastases in regional lymph nodes in Dukes' B colorectal carcinoma: an immunohistochemical study. Eur J Surg. 1996;162:637-642.
40. Andreola S, Leo E, Belli F, et al. Adenocarcinoma of the lower third of the rectum: metastases in lymph nodes smaller than 5 mm and occult micrometastases; preliminary results on early tumor recurrence. Ann Surg Oncol. 2001;8:413-417.
41. Broll R, Schauer V, Schimmelpenning H, et al. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas: an immunohistochemical study. Dis Colon Rectum. 1997;40:1465-1471.
42. Bukholm IR, Bondi J, Wiik P, et al. Presence of isolated tumour cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer. Eur J Surg Oncol. 2003;29:862-866.
43. Choi HJ, Choi YY, Hong SH. Incidence and prognostic implications of isolated tumor cells in lymph nodes from patients with Dukes B colorectal carcinoma. Dis Colon Rectum. 2002;45:750-755; discussion 755-756
44. Clarke G, Ryan E, O'Keane JC, et al. The detection of cytokeratins in lymph nodes of Duke's B colorectal cancer subjects predicts a poor outcome. Eur J Gastroenterol Hepatol. 2000;12:549-552.
45. Cutait R, Alves VA, Lopes LC, et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum. 1991;34:917-920.
46. Davies M, Arumugam PJ, Shah VI, et al. The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer. Clin Transl Oncol. 2008;10:175-179.
47. Fisher ER, Colangelo L, Wieand S, et al. Lack of influence of cytokeratin-positive mini micrometastases in "Negative Node" patients with colorectal cancer: findings from the national surgical adjuvant breast and bowel projects protocols R-01 and C-01. Dis Colon Rectum. 2003;46:1021-1025; discussion 1025-1026
48. Fleming FJ, Hayanga AJ, Glynn F, et al. Incidence and prognostic influence of lymph node micrometastases in rectal cancer. Eur J Surg Oncol. 2007;33:998-1002.
49. Haboubi NY, Abdalla SA, Amini S, et al. The novel combination of fat clearance and immunohistochemistry improves prediction of the outcome of patients with colorectal carcinomas: a preliminary study. Int J Colorectal Dis. 1998;13:99-102.
50. Hara M, Hirai T, Nakanishi H, et al. Isolated tumor cell in lateral lymph node has no influences on the prognosis of rectal cancer patients. Int J Colorectal Dis. 2007;22:911-917.
51. Hitchcock CL, Sampsel J, Young DC, et al. Limitations with light microscopy in the detection of colorectal cancer cells. Dis Colon Rectum. 1999;42:1046-1052.
52. Isaka N, Nozue M, Doy M, et al. Prognostic significance of perirectal lymph node micrometastases in Dukes' B rectal carcinoma: an immunohistochemical study by CAM5.2. Clin Cancer Res. 1999;5:2065-2068.
53. Jeffers MD, O'Dowd GM, Mulcahy H, et al. The prognostic significance of immunohistochemically detected lymph node micro-metastases in colorectal carcinoma. J Pathol. 1994;172:183-187.
54. Kronberg U, Lopez-Kostner F, Soto G, et al. Detection of lymphatic micrometastases in patients with stages I and II colorectal cancer: impact on five-year survival. Dis Colon Rectum. 2004;47:1151-1157.
55. Makin CA, Bobrow LG, Nicholls RJ. Can immunohistology improve detection of lymph-node metastases in large-bowel cancer? Dis Colon Rectum. 1989;32:99-102.
56. Mescoli C, Rugge M, Pucciarelli S, et al. High prevalence of isolated tumour cells in regional lymph nodes from pN0 colorectal cancer. J Clin Pathol. 2006;59:870-874.
57. Messerini L, Cianchi F, Cortesini C, et al. Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma. Hum Pathol. 2006;37:1259-1267.
58. Nakanishi Y, Ochiai A, Yamauchi Y, et al. Clinical implications of lymph node micrometastases in patients with colorectal cancers. A case control study. Oncology. 1999;57:276-280.
59. Nicholson AG, Marks CG, Cook MG. Effect on lymph node status of triple levelling and immunohistochemistry with CAM 5.2 on node negative colorectal carcinomas. Gut. 1994;35:1447-1448.
60. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res. 2002;8:759-767.
61. O'Brien MJ, Zamcheck N, Burke B, et al. Immunocytochemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Assessment of diagnostic value. Am J Clin Pathol. 1981;75:283-290.
62. Oberg A, Stenling R, Tavelin B, et al. Are lymph node micro-metastases of any clinical significance in Dukes stages A and B colorectal cancer? Dis Colon Rectum. 1998;41:1244-1249.
63. Oh TY, Moon SM, Shin US, et al. Impact on prognosis of lymph node micrometastasis and isolated tumor cells in stage II colorectal cancer. J Korean Soc Coloproctol. 2011;27:71-77.
64. Palma RT, Waisberg J, Bromberg SH, et al. Micrometastasis in regional lymph nodes of extirpated colorectal carcinoma: immuno-histochemical study using anti-cytokeratin antibodies AE1/AE3. Colorectal Dis. 2003;5:164-168.
65. Reggiani Bonetti L, Di Gregorio C, De Gaetani C, et al. Lymph node micrometastasis and survival of patients with stage I (Dukes' A) colorectal carcinoma. Scand J Gastroenterol. 2011;46:881-886.
66. Rosenberg R, Friederichs J, Gertler R, et al. Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer. Int J Colorectal Dis. 2004;19:430-437.
67. Rosenberg R, Hoos A, Mueller J, et al. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol. 2002;20:1049-1055.
68. Sasaki M, Watanabe H, Jass JR, et al. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in "node-negative" colorectal cancer. J Gastroenterol. 1997;32:758-764.
69. Schurr PG, Behnke S, Kaifi JT, et al. Central mesenteric lymph node BER-Ep4+ cells in colorectal cancer: challenge to sentinel node concept? Dig Surg. 2007;24:19-27.
70. Shimoyama M, Yamazaki T, Suda T, et al. Prognostic significance of lateral lymph node micrometastases in lower rectal cancer: an immunohistochemical study with CAM5.2. Dis Colon Rectum. 2003;46:333-339.
71. Uribarrena-Amezaga R, Ortego J, Fuentes J, et al. Prognostic value of lymph node micrometastasis in patients with colorectal cancer in Dukes stages A and B (T1-T4, N0, M0). Rev Esp Enferm Dig. 2010;102:176-186.
72. Wang C, Zhou ZG, Wang Z, et al. Mesorectal spread and micrometastasis of rectal cancer studied with large slice technique and tissue microarray. J Surg Oncol. 2005;91:167-172.
73. Yasuda K, Adachi Y, Shiraishi N, et al. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2001;8:300-304.
74. Zheng YC, Tang YY, Zhou ZG, et al. Tumor micrometastases in mesorectal lymph nodes and their clinical significance in patients with rectal cancer. World J Gastroenterol. 2004;10:3369-3373.
75. Zhou ZW, Rieger N, Ruszkiewicz A, et al. Detection of lymph nodes micrometastases in Dukes' A and B colorectal cancer using anti-cytokeratin antibodies AE1/AE3. World J Gastroenterol. 2005;11:3640-3643.
76. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 2003;98:2740-2741.
77. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336-5339.
78. van Deurzen CH, Cserni G, Bianchi S, et al. Nodal-stage classification in invasive lobular breast carcinoma: influence of different interpretations of the pTNM classification. J Clin Oncol. 2010;28:999-1004.
79. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653-663.
80. Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64:415-420.
81. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer. 2009;9:143. [Author reply 143].
82. Detmar M, Hirakawa S. The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med. 2002;196:713-718.
83. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573-583.
84. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162:1951-1960.
85. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer. 1999;80:569-578.